|
Big Advantages
|
|
|
|
|
|
Partnering With CRO |
|
|
|
|
|
CRO as extension for your business |
|
|
|
|
|
 Global financial crisis makes the word seems different as it used to be. Pharmaceutical/biotechnologist companies enter the unprecedented market conditions. It forced them to reinvent themselves in the light of new market conditions. In the most general condition, they have been downsizing, organizing themselves into smaller and more accountable business unit, rationalizing their R & D programs and moving it to outsourced sub contractor. They try to re-focusing and consolidated business on core competencies.
|
|
|
|
|
|
Outsourcing Trends |
|
|
|
|
|
 Outsourcing trends become increasingly in global pharmaceutical company market as many values it gained: superior skills/ expertise, cost saving and increase in operational flexibility.
It seems that outsourced to CRO is an answer for pharma/biotech companies to solve the problem in Clinical Trial. Outsourcing brings benefit for both to start up company and big pharma. For a start-up company, which will often not have enough resources for doing project by their self, including data management, biostatistics, and pharmacovigilance, it will be a cost effective solution to completed trial faster so the product can move to the market. For big pharma, it also the right answer since the clinical trial is a secondary business.
Reuters Business Insight
|
|
|
|
|
|
Accelerate Timeliness for Global Market |
|
|
|
|
|
 The world of pharmaceutical market looks set to undergo a major transformation following the ensuing loss of present blockbuster drugs. The development of new drugs from pre-clinical stage to approval averages about ten years and given enormous development cost.
In recent years, outsourcing has become more strategic in nature as they offer efficient, depth and breadth of capabilities. CRO are capable to completed trial faster and giving more time for marketing time before their patent expires.
Benchmarking study by KMR Consulting of 2,800 Phase III trials in 2000.
Sources: Frost & Sullivan, 2003; Reuters; Data Monitor
|
|
|
|
|
|
Reduction or Competitive Cost |
|
|
|
|
|
Efficient of clinical trial are going to be vital for success of all pharmaceutical companies. In 2000, cost to develop a new drug average US $ 800 millions, with time cost accounting for half of that amount. Accelerate timelines is one of CRO specialty, it could effect in cost reduction significantly.
Tufts Center for The Study of Drug Development
|
|
|
|
